Literature DB >> 26095930

CD47 deficiency ameliorates autoimmune nephritis in Fas(lpr) mice by suppressing IgG autoantibody production.

Lei Shi1,2, Zhen Bian1,2, Celia X J Chen2, Ya-Nan Guo2, Zhiyuan Lv2, Caihong Zeng3, Zhihong Liu3, Ke Zen1,2, Yuan Liu2.   

Abstract

CD47, a self-recognition marker, plays an important role in both innate and adaptive immune responses. To explore the potential role of CD47 in activation of autoreactive T and B cells and the production of autoantibodies in autoimmune disease, especially systemic lupus erythematosus (SLE), we have generated CD47 knockout Fas(lpr) (CD47(-/-) -Fas(lpr) ) mice and examined histopathological changes in the kidneys, cumulative survival rates, proteinuria, extent of splenomegaly and autoantibodies, serum chemistry and immunological parameters. In comparison with Fas(lpr) mice, CD47(-/-) -Fas(lpr) mice exhibit a prolonged lifespan and delayed autoimmune nephritis, including glomerular cell proliferation, basement membrane thickening, acute tubular atrophy and vacuolization. CD47(-/-) -Fas(lpr) mice have lower levels of proteinuria, associated with reduced deposition of complement C3 and C1q, and IgG but not IgM in the glomeruli, compared to age-matched Fas(lpr) mice. Serum levels of antinuclear antibodies and anti-double-stranded DNA antibodies are significantly lower in CD47(-/-) -Fas(lpr) than in Fas(lpr) mice. CD47(-/-) -Fas(lpr) mice also display less pronounced splenomegaly than Fas(lpr) mice. The mechanistic studies further suggest that CD47 deficiency impairs the antigenic challenge-induced production of IgG but not IgM, and that this effect is associated with reduction of T follicular cells and impairment of germinal centre development in lymphoid tissues. In conclusion, our results demonstrate that CD47 deficiency ameliorates lupus nephritis in Fas(lpr) mice via suppression of IgG autoantibody production.
Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  CD47; T follicular cell; antibody production; autoimmunity

Mesh:

Substances:

Year:  2015        PMID: 26095930      PMCID: PMC4607582          DOI: 10.1002/path.4574

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  49 in total

Review 1.  Present and future of the autoimmunity laboratory.

Authors:  José M González-Buitrago; Concepción González
Journal:  Clin Chim Acta       Date:  2005-08-26       Impact factor: 3.786

Review 2.  Helper T cell-regulated B cell immunity.

Authors:  L J McHeyzer-Williams; L P Malherbe; M G McHeyzer-Williams
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

Review 3.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 4.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.

Authors:  Charles A Dinarello
Journal:  Blood       Date:  2011-02-08       Impact factor: 22.113

5.  Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes.

Authors:  Leendert A Trouw; Tom W L Groeneveld; Marc A Seelen; Jacques M G J Duijs; Ingeborg M Bajema; Frans A Prins; Uday Kishore; David J Salant; J Sjef Verbeek; Cees van Kooten; Mohamed R Daha
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

Review 6.  Homeostasis of naive and memory T cells.

Authors:  Charles D Surh; Jonathan Sprent
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

Review 7.  The pathogenesis, diagnosis and treatment of lupus nephritis.

Authors:  Noa Schwartz; Beatrice Goilav; Chaim Putterman
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

8.  Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis.

Authors:  Ying Tan; Di Song; Li-hua Wu; Feng Yu; Ming-hui Zhao
Journal:  BMC Nephrol       Date:  2013-03-19       Impact factor: 2.388

9.  CD47 ligation selectively downregulates human interleukin 12 production.

Authors:  M Armant; M N Avice; P Hermann; M Rubio; M Kiniwa; G Delespesse; M Sarfati
Journal:  J Exp Med       Date:  1999-10-18       Impact factor: 14.307

10.  The Pathogenesis of Lupus Nephritis.

Authors:  Rosalie M Sterner; Stella P Hartono; Joseph P Grande
Journal:  J Clin Cell Immunol       Date:  2014-04
View more
  5 in total

1.  Donor SIRPα polymorphism modulates the innate immune response to allogeneic grafts.

Authors:  Hehua Dai; Andrew J Friday; Khodor I Abou-Daya; Amanda L Williams; Steven Mortin-Toth; Matthew L Nicotra; David M Rothstein; Warren D Shlomchik; Takashi Matozaki; Jeffrey S Isenberg; Martin H Oberbarnscheidt; Jayne S Danska; Fadi G Lakkis
Journal:  Sci Immunol       Date:  2017-06-23

2.  Stabilized β-Catenin Ameliorates ALPS-Like Symptoms of B6/lpr Mice.

Authors:  Xiaoxie Xu; Jun Huang; Mei Zhao; Huanpeng Chen; Jinhua Mo; Xiaoqing Zhou; Qiao Su; Bolan Yu; Zhaofeng Huang
Journal:  J Immunol Res       Date:  2017-11-09       Impact factor: 4.818

3.  The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis.

Authors:  Kai-Uwe Jarr; Jianqin Ye; Yoko Kojima; Zhongde Ye; Hua Gao; Sofie Schmid; Lingfeng Luo; Richard A Baylis; Mozhgan Lotfi; Nicolas Lopez; Anne V Eberhard; Bryan Ronain Smith; Irving L Weissman; Lars Maegdefessel; Nicholas J Leeper
Journal:  Nat Cardiovasc Res       Date:  2022-03-07

4.  CD47 Potentiates Inflammatory Response in Systemic Lupus Erythematosus.

Authors:  Jin Kyun Park; Ye Ji Lee; Ji Soo Park; Eun Bong Lee; Yeong Wook Song
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

5.  CD47 Expression in Natural Killer Cells Regulates Homeostasis and Modulates Immune Response to Lymphocytic Choriomeningitis Virus.

Authors:  Pulak Ranjan Nath; Arunakumar Gangaplara; Dipasmita Pal-Nath; Ajeet Mandal; Dragan Maric; John M Sipes; Maggie Cam; Ethan M Shevach; David D Roberts
Journal:  Front Immunol       Date:  2018-12-20       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.